Comparison of the FXG™: RESP (Asp++) real-time PCR assay with direct immunofluorescence and calcofluor white staining for the detection of Pneumocystis jirovecii in respiratory specimens

Authors: Seah, Christine; Richardson, Susan E.; Tsui, George; Yu, Billy; Thornback, John1; McTaggart, Lisa; Boggild, Andrea2; Wengenack, Nancy L.3; Zhang, Sean X.

Source: Medical Mycology, Volume 50, Number 3, April 2012 , pp. 324-327(4)

Publisher: Informa Healthcare

Buy & download fulltext article:

OR

Price: $34.96 plus tax (Refund Policy)

Abstract:

We compared the FXG™: RESP (Asp ++) real-time PCR assay (Myconostica Ltd) with two microscopic staining methods (direct immunofluorescence [IFA] and calcofluor white) for the detection of Pneumocystis jirovecii in 411 respiratory specimens submitted for P. jirovecii examination. We considered the specimen to be microscopically positive if the organism could be visualized through the use of either IFA or calcofluor white. A second, published real-time PCR assay targeting the cdc2 gene of P. jirovecii was used to adjudicate those specimens that were microscopically negative but Myconostica PCR positive. The Myconostica PCR positive samples were deemed to be true positives if they were concordant with microscopically positive results or if they were positive by the second PCR assay. As a result, the Myconostica PCR assay was found to be more sensitive than the two microscopy methods in detecting P. jirovecii (10.5% true positivity rate by PCR, 8.0% by immunofluorescence, and 7.1% by calcofluor white). The Myconostica PCR assay showed 93.5% sensitivity, 95.1% specificity, 70.5% positive predictive value, and 99.1% negative predictive value. Its high negative predictive value suggests a role of the Myconostica PCR assay in ruling out Pneumocystis pneumonia.

Keywords: PCR; Pneumocystis jirovecii; calcofluor white; detection; immunofluorescence

Document Type: Research Article

DOI: http://dx.doi.org/10.3109/13693786.2011.598878

Affiliations: 1: §Myconostica Ltd, Manchester, UK 2: †Department of Laboratory Medicine and Pathobiology, University of Toronto 3: ##Division of Clinical Microbiology, Mayo Clinic, MN, USA

Publication date: April 1, 2012

More about this publication?

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page